Act like a helpful tutor and exlain me :
Acute otitis media (AOM) is the inflammation of the inner ear. It usually presents abruptly with ear pain, often following an upper respiratory infection. In

Question

Act like a helpful tutor and exlain me : 
Acute otitis media (AOM) is the inflammation of the inner ear. It usually presents abruptly with ear pain, often following an upper respiratory infection. In young children this may result in pulling at the ear, increased crying, and poor sleep. Decreased eating and a fever may also be present. Chronic otitis media may result in hearing loss, which affects a child’s ability to learn. Worldwide, AOM affects about 11% of people a year (about 710 million cases). AOM affects about 80% of children before the age of 10, resulting in 2,400 deaths in 2013. A leading cause of otitis media often is Streptococcus pneumonia, a pathogenic bacterium.

In order to find a better way to prevent AOM, researchers conducted a randomized, double blind trial comparing a new pneumococcal vaccine to the current meningococcal vaccine. A total of 5,451 children under the age of 5 were involved in the study. Of these children, 2,724 revived the current meningococcal conjugate vaccine, and the remainder received the new pneumococcal vaccine. Overall, 137 children tested positive for Streptococcus pneumonia otitis media, with 11 in the control group and the remainder i

VIPSolutions · Accepted Answer

Great! Let’s take this step by step.

---

### 1. Complete the 2x2 Table

Let’s clarify our variables:

- **Exposure/Intervention:** Type of vaccine received  
    - **Treatment group:** New pneumococcal vaccine  
    - **Control group:** Current meningococcal conjugate vaccine  
- **Outcome:** Developed AOM due to *Streptococcus pneumoniae* (Yes/No)

**Data from the problem:**

- Total children: **5,451**
- Control (meningococcal): **2,724**
- Treatment (pneumococcal): **5,451 - 2,724 = 2,727**
- Number who developed AOM (total): **137**
    - In control: **11**
    - In treatment: **137 - 11 = 126**

**2x2 Table:**

|                            | Developed AOM (Yes) | Did NOT Develop AOM (No) | Total      |
|----------------------------|--------------------|--------------------------|------------|
| **Treatment (Pneumococcal)** | 126                | 2,727 - 126 = 2,601      | 2,727      |
| **Control (Meningococcal)**  | 11                 | 2,724 - 11 = 2,713       | 2,724      |
| **Total**                  | 137                | 2,601 + 2,713 = 5,314    | 5,451      |

---

### 2. What type of study is this? How do you know? Be specific.

**This is a randomized, double-blind controlled trial (RCT).**

**Why?**  
- **Randomized:** Participants were randomly assigned to two groups.
- **Double-blind:** Neither participants nor researchers knew which group each child was in (reduces bias).
- **Controlled:** There is an intervention (new vaccine) and a control (current vaccine).
- **Prospective:** Researchers followed subjects forward in time to observe outcomes.

---

### 3. Which group is the treatment group, and which group is the control group?

- **Treatment group:** Received the **new pneumococcal vaccine** (2,727 children)
- **Control group:** Received the **current meningococcal conjugate vaccine** (2,724 children)

---

### 4. Is this a superiority test or an equivalence test? How do you know?

**This is a superiority test.**

**Why?**  
Researchers are comparing a **new intervention** (pneumococcal vaccine) to see if it is **better (superior)** at preventing AOM caused by *Streptococcus pneumoniae* than the current standard (meningococcal vaccine). The goal is to show that the new vaccine reduces disease more than the control.

---

### 5. State and calculate the appropriate measure of association, and explain what it means in words.

**Appropriate Measure:**  
Because this is a randomized trial comparing risk of disease, the **Relative Risk (RR)** is appropriate.

#### **Calculate Risks:**

- **Risk in treatment (pneumococcal):**  
  $ \frac{126}{2,727} = 0.0462 $ (**4.62%**)

- **Risk in control (meningococcal):**  
  $ \frac{11}{2,724} = 0.00404 $ (**0.404%**)

#### **Calculate Relative Risk (RR):**

$ RR = \frac{\text{Risk in Treatment}}{\text{Risk in Control}} = \frac{0.0462}{0.00404} \approx 11.43 $

#### **Interpretation:**

**In words:**  
Children who received the new pneumococcal vaccine were about **11 times more likely** to develop *Streptococcus pneumoniae* AOM compared to those who received the meningococcal vaccine.

---

#### **Summary Table**

|                      | Developed AOM | Did NOT Develop AOM | Total  |
|----------------------|---------------|---------------------|--------|
| Pneumococcal         | 126           | 2,601               | 2,727  |
| Meningococcal        | 11            | 2,713               | 2,724  |

---

**Note:**  
- The new vaccine appears to be associated with a **higher** risk of AOM due to *Streptococcus pneumoniae*, not lower. This suggests the new vaccine is **not effective** (and may even be harmful) compared to the control.
- In a well-designed superiority trial, we'd hope RR < 1 for a preventative vaccine.

---

Let me know if you’d like to discuss why the new vaccine might have performed worse, or if you need help with further calculations or interpretations!

✨ VIPSolutions

Question:

Final Answer:

📢 Instructions:

Study Help, Fast Answers

✨ VIPSolutions

Question:

Final Answer:

📢 Instructions:

Related Answers

Study Help, Fast Answers